Who is amplifying whom in the ASCO 2026 Annual Meeting myeloma conversation on X. Nodes are accounts; edges are retweets, quotes, and mentions. Node size scales with impressions; ring color marks account type. Use the Myeloma Trial filter to isolate the sub-network behind any single trial.
← Back to the myeloma Attendee NetworkThis visualization is compiled by the KOL Pulse research team from curated myeloma tweets tagged to ASCO 2026 and enriched with engagement identities via the X API. Every account is classified against the KOL Pulse registry (verified US physicians are cross-referenced with CMS Open Payments). No accounts are fabricated; all tweet counts and impressions are as reported by X.
It maps the retweet, quote, and mention relationships among 600 X/Twitter accounts discussing myeloma research at ASCO 2026 Annual Meeting. Node size reflects impressions; ring color reflects account type (verified US physician, international MD, media/org, amplifier, or mentioned). 54 accounts authored original myeloma tweets.
Use the Myeloma Trial dropdown in the left control panel. Selecting a trial (for example AQUILA, CARTITUDE-4, PERSEUS, DREAMM-7, or IMROZ) shows only the accounts and edges tied to that trial. An account is tied to a trial when it authored a tweet tagged to that trial or engaged a KOL who did. Choose 'All myeloma trials' to return to the full network.
Accounts classified as US physicians are cross-referenced against the CMS Open Payments dataset and the KOL Pulse classified registry. They render with a gold ring and a US badge.
The filterable trials (each tied to at least three curated tweets) are MajesTEC-9, SUCCESSOR-2, ENDURANCE/E1A11, MonumenTAL-3, MajesTEC-3, MajesTEC-4, MonumenTAL-6, CARTITUDE-4, CEPHEUS, PERSEUS, DREAMM-9, ImmunoPRISM, DREAMM-7.
KOL Pulse curated 266 myeloma tweets tagged to ASCO 2026 and enriched them with engagement identities (who retweeted and quoted each post) via the X API. Accounts were then classified using the KOL Pulse registry.